What is Dostarlimab?

What is Dostarlimab?

 

For the first time in history, Dostarlimab, a monoclonal antibody drug, has been termed as a 'potential' cure for cancer.

 

A clinical trial conducted by the US-based Memorial Sloan Kettering Cancer Center in 2022 discovered that all 18 rectal cancer patients found that their cancer had disappeared within six months after receiving an experimental treatment of this promising breakthrough medication. Participants of the trial were given at least nine doses of the drug every three weeks for six months.

After the completion of the duration, all patients showed a clinical complete response with no signs of the tumour. The treatment